Clinical and immunological aspects of HLA class I deficiency

QJM: An International Journal of Medicine

Volumn 98, Issue 10, 2005, Pages 719-727

  Zimmer, Jacques ^a   Andres E ^b   Donato, L ^b   Hanau, D ^c   Hentges, F ^a   de la Salle, H ^c  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; AZATHIOPRINE; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROMYCIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; METHOTREXATE; PEPTIDE; PROTEIN SUBUNIT; PSORALEN; STEROID; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; VIRUS ANTIGEN;

AIRWAY; ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BACTERIAL INFECTION; BARE LYMPHOCYTE SYNDROME; BRONCHIECTASIS; CYTOTOXIC T LYMPHOCYTE; DISEASE EXACERBATION; EARLY DIAGNOSIS; EFFECTOR CELL; FLOW CYTOMETRY; GENE MUTATION; GENE THERAPY; GRANULOMATOUS INFLAMMATION; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; LUNG DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PUVA; REVIEW; SEROTYPING; SKIN ULCER; SUPPRESSOR CELL; SYMPTOM; VIRUS INFECTION;

EID: 27644538518     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci112     Document Type: Review

References (40)

1. Grommé M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002; 39:181-202.
2. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998; 16:323-58.
3. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996; 14:369-96.
4. Watts C, Powis S. Pathways of antigen processing and presentation. Rev Immunogenetics 1999; 1:60-74.
5. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999; 73:1-77.
6. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999; 401:921-3.
7. Gabathuler R, Reith G, Kolaitis G, et al. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 1994; 180:1415-25.
8. Yabe T, Kawamura S, Sato M, et al. A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to a deletion of 4 exons by Alu-mediated recombination. Blood 2002; 100:1496-8.
9. De la Salle H, Donato L, Zimmer J, et al. HLA class I deficiencies. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A molecular and genetic approach. New York, Oxford University Press, 1999:181-8.
10. Gadola SD, Moins-Teisserenc HT, Trowsdale J, et al. TAP deficiency syndrome. Clin Exp Immunol 2000; 121:173-8.
11. De la Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 1994; 265:237-41.
12. Donato L, de la Salle H, Hanau D, et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr 1995; 127:895-900.
13. Donato L, de la Salle H, Hanau D, et al. Déficit en antigènes HLA de classe I et bronchiectasies familiales: Revue de la littérature avec étude clinique et biologique. Rev Fr Allergol 1997; 37:127-34.
14. De la Salle H, Zimmer J, Fricker D, et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest 1999; 103:R9-13.
15. Furukawa H, Murata S, Yabe T, et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999; 103:755-8.
16. Maeda H, Hirata R, Chen RF, et al. Defective expression of HLA class I antigens: A case of the bare lymphocyte syndrome without immunodeficiency. Immunogenetics 1985; 21:549-58,
17. Plebani A, Monafo V, Cattaneo R, et al. Defective expression of HLA class I and CD1 a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol 1996; 35:814-18.
18. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low Surface expression of HLA class I-molecules. Lancet 1999; 354:1598-603.
19. Teisserenc H, Schmitt W, Blake N, et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett 1997; 57:183-7.
20. Matamoros N, Milà J, Llano M, et al. Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency. Clin Exp Immunol 2001; 125:274-82.
21. Markel G, Mussafi H, Ling KL, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004; 103:1770-8.
22. Sugiyama Y, Maeda H, Okumura K, Takaku F. Progressive sinobronchiectasis associated with the 'Bare Lymphocyte Syndrome' in an adult. Chest 1986; 89:398-401.
23. Payne R, Brodsky F, Peterlin BM, Young LM. Bare lymphocytes without immunodeficiency. Hum Immunol 1983; 6:219-27.
24. De la Salle H, Saulquin X, Mansour I, et al. Asymptomatic deficiency in the peptide transporter associated to antigen processing. Clin Fxp Immunol 2002; 128:525-31.
25. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: Lessons from a disease. Annu Rev Immunol 1996; 14:301-31.
26. Gobin SJ, Peijnenburg A, van Eggermond M, et al. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and β2-microglobulin genes. Immunity 1998; 9:531-41.
27. Furukawa H, Yabe T, Watanabe K, et al. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum Immunol 1999; 60:32-40.
28. Crespi C, Julià MR, Munoz-Saa I, et al. Skewed inhibitory receptors expression in a TAP2-deficient patient. Immunol Lett 2003; 68:149-53.
29. De la Salle H, Houssaint E, Peyrat MA, et al. Human peptide transporter deficiency. Importance of HLA-B in the presentation of TAP-independent EBV antigens. J Immunol 1997; 158:4555-63.
30. Zimmer J, Donato L, HanaU D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 1998; 187:117-22.
31. Zimmer J, Donato L, Hanau D, et al. Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol 1999; 29:1286-91.
32. Vitale M, Zimmer J, Castriconi R, et al. Analysis of natural killer cells in TAP2-deficient patients: Expression of functional triggering receptors and evidence for the presence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 2002; 99:1723-9.
33. Wu MF, Raulet DH. Class I-deficient hemopoietic cells and nonhemopoietic cells dominantly induce unresponsiveness of natural killer cells to class I-deficient bone marrow cell grafts. J Immunol 1997; 158:1628-33.
34. Azuma A, Keicho N, Furukawa H, et al. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:312-13.
35. Sugihara E, Koyanagi T, Niizeki T, et al. Macrolide antibiotics directly reduce active oxygen generation by neutrophils in human peripheral blood. Kurume Med J 2003; 50:9-15.
36. Keicho N, Kudoh S. Diffuse panbronchiolitis: Role of macrolides in therapy. Am J Respir Med 2002; 1:119-31.
37. Schultz H, Schinke S, Weiss I, et al. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: Possible role in susceptibility to Gram-negative bacterial infections. Clin Exp Immunol 2003; 133:252-9.
38. Raghavan M. Immunodeficiency due to a defective antigen processing: The molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999; 103:595-6.
39. Campbell DJ, Serwold T, Shastri N. Bacterial proteins can be processed by macrophages in a transporter associated with antigen processing-independent, cysteine protease-dependent manner for presentation by MHC class I molecules. J Immunol 2000; 164:168-75.
40. De la Calle-Martin O, Hernandez M, Ordi J, et al. Familial CD8 deficiency due to a mutation in the CD8α gene. J Clin Invest 2001; 108:117-23.